Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:51 UTC |
---|
HMDB ID | HMDB0015058 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Levosimendan |
---|
Description | Levosimendan, also known as simdax, belongs to the class of organic compounds known as phenylhydrazines. Phenylhydrazines are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent attached to a phenyl group. Levosimendan is marketed as a 2.5 mg/mL concentrated solution for IV infusion. Levosimendan is a drug which is used for short term treatment of acutely decompensated severe chronic heart failure (chf). also being investigated for use/treatment in heart disease. Levosimendan is a strong basic compound (based on its pKa). It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. However, the drug was proven to be superior to dobutamine for treating patients with a history of CHF or those on beta-blocker therapy when they are hospitalized with acute decompensations.The Orion Corporation originally developed levosimendan and applied for a new drug application in 1998 in the U.S. In total, the clinical data base includes more than 3500 patients in Phase IIb and III double-blind randomized studies. Levosimendan (INN) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Initially, Orion obtained the approval to market the drug in Sweden in 2000. It is marketed under the trade name Simdax (Orion Corporation). Common adverse drug reactions (≥1% of patients) associated with levosimendan therapy include: headache, hypotension, arrhythmias (atrial fibrillation, extrasystoles, Atrial tachycardia, ventricular tachycardia), myocardial ischaemia, hypokalaemia and/or nausea (Rossi, 2006). |
---|
Structure | C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1 |
---|
Synonyms | Value | Source |
---|
Levosimendanum | ChEBI | Simdax | ChEBI | Levosimedan | HMDB | Simadax | HMDB | Dextrosimendan | HMDB | ((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile | HMDB | Simendan | HMDB |
|
---|
Chemical Formula | C14H12N6O |
---|
Average Molecular Weight | 280.2847 |
---|
Monoisotopic Molecular Weight | 280.107259036 |
---|
IUPAC Name | 1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide |
---|
Traditional Name | levosimendan |
---|
CAS Registry Number | 141505-33-1 |
---|
SMILES | C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 |
---|
InChI Identifier | InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1 |
---|
InChI Key | WHXMKTBCFHIYNQ-SECBINFHSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenylhydrazines. Phenylhydrazines are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent attached to a phenyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Phenylhydrazines |
---|
Direct Parent | Phenylhydrazines |
---|
Alternative Parents | |
---|
Substituents | - Phenylhydrazine
- Pyridazinone
- Pyridazine
- Carboxylic acid derivative
- Hydrazone
- Carbonitrile
- Nitrile
- Organoheterocyclic compound
- Azacycle
- Organic nitrogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.088 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Levosimendan,1TMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C)N=C1C1=CC=C(NN=C(C#N)C#N)C=C1 | 2914.1 | Semi standard non polar | 33892256 | Levosimendan,1TMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C)N=C1C1=CC=C(NN=C(C#N)C#N)C=C1 | 2777.3 | Standard non polar | 33892256 | Levosimendan,1TMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C)N=C1C1=CC=C(NN=C(C#N)C#N)C=C1 | 5568.6 | Standard polar | 33892256 | Levosimendan,1TMS,isomer #2 | C[C@@H]1CC(=O)NN=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C)C=C1 | 2989.1 | Semi standard non polar | 33892256 | Levosimendan,1TMS,isomer #2 | C[C@@H]1CC(=O)NN=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C)C=C1 | 2850.5 | Standard non polar | 33892256 | Levosimendan,1TMS,isomer #2 | C[C@@H]1CC(=O)NN=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C)C=C1 | 5682.7 | Standard polar | 33892256 | Levosimendan,2TMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C)N=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C)C=C1 | 2779.7 | Semi standard non polar | 33892256 | Levosimendan,2TMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C)N=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C)C=C1 | 2784.3 | Standard non polar | 33892256 | Levosimendan,2TMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C)N=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C)C=C1 | 5395.4 | Standard polar | 33892256 | Levosimendan,1TBDMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C(C)(C)C)N=C1C1=CC=C(NN=C(C#N)C#N)C=C1 | 3199.4 | Semi standard non polar | 33892256 | Levosimendan,1TBDMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C(C)(C)C)N=C1C1=CC=C(NN=C(C#N)C#N)C=C1 | 3003.7 | Standard non polar | 33892256 | Levosimendan,1TBDMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C(C)(C)C)N=C1C1=CC=C(NN=C(C#N)C#N)C=C1 | 5624.5 | Standard polar | 33892256 | Levosimendan,1TBDMS,isomer #2 | C[C@@H]1CC(=O)NN=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C(C)(C)C)C=C1 | 3187.6 | Semi standard non polar | 33892256 | Levosimendan,1TBDMS,isomer #2 | C[C@@H]1CC(=O)NN=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C(C)(C)C)C=C1 | 3066.3 | Standard non polar | 33892256 | Levosimendan,1TBDMS,isomer #2 | C[C@@H]1CC(=O)NN=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C(C)(C)C)C=C1 | 5666.2 | Standard polar | 33892256 | Levosimendan,2TBDMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C(C)(C)C)N=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C(C)(C)C)C=C1 | 3205.2 | Semi standard non polar | 33892256 | Levosimendan,2TBDMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C(C)(C)C)N=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C(C)(C)C)C=C1 | 3187.0 | Standard non polar | 33892256 | Levosimendan,2TBDMS,isomer #1 | C[C@@H]1CC(=O)N([Si](C)(C)C(C)(C)C)N=C1C1=CC=C(N(N=C(C#N)C#N)[Si](C)(C)C(C)(C)C)C=C1 | 5354.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Levosimendan GC-MS (Non-derivatized) - 70eV, Positive | splash10-0l6r-2190000000-95c9a8cdabf61909acac | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Levosimendan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Levosimendan LC-ESI-qTof , Positive-QTOF | splash10-001i-0390000000-88e46fb95115eb7b2d26 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Levosimendan , positive-QTOF | splash10-001i-0390000000-88e46fb95115eb7b2d26 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 10V, Positive-QTOF | splash10-01q9-1290000000-6d9a7b470636a54e587e | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 20V, Positive-QTOF | splash10-0gx0-1390000000-90a2f0832ca10328f83c | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 40V, Positive-QTOF | splash10-000f-9620000000-c8bae586e1e611afe4c6 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 10V, Negative-QTOF | splash10-004i-4090000000-267416d8b7d793ecaf28 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 20V, Negative-QTOF | splash10-0006-9150000000-f151e544be5e67b5ad21 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 40V, Negative-QTOF | splash10-004l-9010000000-532ba1389514437da33a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 10V, Positive-QTOF | splash10-001i-0090000000-5a694436ae56bc0fded4 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 20V, Positive-QTOF | splash10-001i-0190000000-47192e7bd78a3e6e189b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 40V, Positive-QTOF | splash10-000i-1930000000-5a28d318150afb2c5a9c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 10V, Negative-QTOF | splash10-004i-0090000000-d2087bfe0706f27ab273 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 20V, Negative-QTOF | splash10-004i-2090000000-6f5783406fb63b34609e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levosimendan 40V, Negative-QTOF | splash10-0aor-5490000000-cd828b665b63c98858cb | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Kasikcioglu HA, Cam N: A review of levosimendan in the treatment of heart failure. Vasc Health Risk Manag. 2006;2(4):389-400. [PubMed:17323593 ]
- Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007 May 2;297(17):1883-91. [PubMed:17473298 ]
- MedicinesComplete [Link]
|
---|